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Abstract 
We report on a 63-year-old woman, previously in good health, who had undergone 
nephrectomy for clear cell renal cell carcinoma in 2002. Because of systemic relapse with 
multiple lung metastases in 2006, the patient was treated with sunitinib 50 mg daily on a 
4-weeks on-/2-weeks off-schedule. After 3 years of treatment, she developed a purpuric 
rash on her feet and trunk. Biopsy revealed leukocytoclastic vasculitis. No other organ 
involvement was diagnosed. She was started on oral prednisone 30 mg daily with rapid 
resolution of the vasculitic skin lesions. Sunitinib was temporally discontinued and 
reintroduced at the same dose level. Reappearance of a less serious vasculitis after 2 
cycles of re-treatment was resolved in the weeks off-treatment and by reducing the dose 
of sunitinib along with 5 mg of prednisone daily. One year after the diagnosis, the 
patient is still on this therapy. Oncology providers should be aware of this rare but 
potentially serious, possible adverse effect of sunitinib. 
 
Introduction 
Renal cell carcinoma (RCC) is the third most common malignancy of the urinary tract 
and accounts for 3% of all adult malignancies. Although cure can be achieved by surgery 
in patients with localized disease, more than a quarter of patients present with advanced 
disease, and one-third of patients who undergo resection of localized disease will 
experience a recurrence [1]. Vascular endothelial growth factor (VEGF) is now 
recognized as a target in the treatment of metastatic RCC (mRCC), and several inhibitors 
of the tyrosine kinases of its receptors have been established in the treatment of mRCC [1, Case Rep Oncol 2011;4:385–391 
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2]. Sunitinib malate (SUTENT; Pfizer Inc., New York, N.Y., USA) is an oral, 
multitargeted tyrosine kinase inhibitor (TKI) of VEGF receptors (VEGFRs), platelet-
derived growth factor receptors (PDGFRs), stem cell factor receptor, FMS-like tyrosine 
kinase 3 receptor, colony-stimulating factor 1 receptor, and glial cell line-derived 
neurotrophic factor receptor (rearranged during transfection). In RCC, sunitinib’s 
mechanism of action is thought to occur through inhibition both of the endothelial cell 
VEGF pathway and PDGFR-β expression in pericytes. Sunitinib is approved for the 
treatment of mRCC in the first-line setting following the results of a randomized phase III 
trial demonstrating its superiority compared with interferon-α [1]. Sunitinib, like other 
multikinase inhibitors, is responsible for a high incidence of a variety of skin disorders 
[3]. In phase II and III studies cutaneous side effects were reported in more than 20% of 
patients. These side effects are usually mild with only 2–5% of grade 3 or 4 toxicities 
reported. The most common are hand-foot syndrome, periorbital edema, hair 
depigmentation, skin discoloration, subungual splinter hemorrhages, and genital rash [3, 
4]. The pathophysiology of skin changes is largely unknown and all cutaneous 
manifestations cannot be attributed to the same mechanism. For example, hair 
depigmentation may be due to the inhibition of the stem cell factor or cKIT signaling, 
while periorbital edema is probably secondary to increased vascular permeability due to 
PDGFR inhibition [4]. Systemic manifestations, such as vasculitis, as a consequence of 
sunitinib treatment have been rarely reported. We hereby report a case of leukocytoclastic 
vasculitis, successfully treated with oral prednisone, not requiring permanent interruption 
of sunitinib.  
Case Presentation 
A 63-year-old woman underwent a right nephrectomy for a stage II clear cell RCC in 2002. She had 
no previous medical history and was a nonsmoker. In 2006, she presented with cough, low fever and 
anemia. The chest computed tomography (CT) scan showed multiple lung metastases, and abdominal 
CT scan showed a tumor of the left kidney, suggestive of a second primary malignancy. CT-guided 
biopsy set the histological confirmation of the systemic relapse of RCC. The patient was initially treated 
with interferon-α, which was soon discontinued due to intolerable toxicity, mainly pyrexia and fatigue. 
She was started on sunitinib 50 mg daily on a 4-weeks on-/2-weeks off-schedule. Six months later, she 
achieved a partial response in the lungs. After 3 years of treatment, pulmonary metastases remain in 
remission, while the renal mass remains stable. During that period, she presented with several toxicities, 
the most serious being hypertension, skin toxicity and hypothyroidism. All toxicities were lower than 
grade 3 and were appropriately managed without dose reduction or treatment delays. In September 
2009 and after having completed almost 3 years on sunitinib treatment, the patient developed a 
gangrene eruption on her feet (fig. 1). There was no hematological or biochemical abnormality and 
urinalysis was normal (table 1). She was examined by a dermatologist; skin biopsy was obtained and set 
the diagnosis of leukocytoclastic vasculitis (fig. 2). Anti-dsDNA, ANA, AMA, ASMA, p-ANCA, and c-
ANCA were negative, while rheumatoid factor and C3 and C4 levels were within normal limits (table 1). 
CT scans of the thorax and abdomen showed no evidence of disease progression. Concomitant 
medication included hydrochlorothiazide for the last 3 years and levothyroxine sodium for the last 2 
years (T4). The skin lesions were attributed to drug toxicity. Concomitant medication has been 
described in the literature as a possible cause of vasculitis. We suppose that sunitinib was the most likely 
cause, since this manifestation has been only rarely described with the other medication the patient was 
receiving. The patient discontinued sunitinib treatment and was started on oral prednisone 30 mg daily 
with significant improvement of the vasculitic lesions. Sunitinib was reintroduced at full dose but a less 
serious vasculitis reappeared after the first 2 cycles. The sunitinib dose was reduced to 37.5 mg. The dose 
of prednisone had been gradually reduced and maintained at 5 mg b.i.d. because of the reappearance of 
a few lesions at lower doses. After lowering the sunitinib dose to 35 mg, along with the low dose of 
prednisone, no clinical sign of reappearance of vasculitis has been observed 1 year after the diagnosis.  Case Rep Oncol 2011;4:385–391 
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Discussion 
Leukocytoclastic vasculitis is an immune complex mediated disease predominantly 
involving small vessels of the skin (also known as cutaneous leukocytoclastic angiitis), 
with occasional involvement of other organ systems. Its severity can range from benign, 
self-limiting, cutaneous eruption to a life-threatening disease with multiple organ failure. 
Cutaneous vasculitis manifests as palpable purpura of the lower extremities. It can be 
associated with drugs (propylthiouracil, hydralazine, hydrochlorothiazide and 
levothyroxine sodium colony-stimulating factors, interleukin-2, allopurinol, cefaclor, 
minocycline, D-pencillamine, phenytoin, isotretinoin and methotrexate) or it can be a 
component of other disease such as infections, (subacute bacterial endocarditis, Epstein-
Bar virus, HIV, chronic active hepatitis, etc.), connective tissue diseases, ulcerative colitis, 
congenital deficiencies of various complement components, retroperitoneal fibrosis and 
malignancies (hematopoietic neoplasias and solid tumors) [5]. Paraneoplastic 
[lymphoproliferative-, myeloproliferative- (more frequently) or carcinoma-induced] 
vasculitis represents less than 5% of all cases of cutaneous leukocytoclastic angiitis and 
improves with treatment of the tumor. Leukocytoclastic vasculitis has been rarely 
reported in association with RCC as the initial manifestation of the disease [6]. It is 
supposed that RCC patients have an impairment of their immune system which manifests 
in a shift from type 1 to type 2 immune response [7]. In contrast to this 
immunosuppressive theory of RCC patients, autoimmune diseases and specifically 
vasculitic diseases, such as Wegener’s granulomatosis [8], Henoch-Schönlein purpura [9], 
and leukocytoclastic vasculitis [6, 8–11], have been rarely described as the first clinical 
manifestation of the disease. Our literature review yielded few cases of leukocytoclastic 
vasculitis associated with antineoplastic therapy with TKIs. Two cases have been 
described in patients receiving erlotinib, a TKI of EGFR [12], while 2 cases of small vessel 
vasculitis have also been reported in association with the multikinase inhibitors imatinib 
and sorafenib [13]. There is only 1 report of leukocytoclastic vasculitis with sunitinib 
during a phase I study [14]. It was described in a biopsy from genital rash. No 
information about the treatment and the outcome was reported. In our case, we consider 
it to be a drug adverse event, specifically of sunitinib, since all other possible causes have 
been excluded. More importantly, vasculitis resolved after the discontinuation of 
sunitinib, while all other medication was continued after its discontinuation. The 
causality is further supported by the reappearance of vasculitis following the 
reintroduction of sunitinib. This could be a manifestation of paraneoplastic syndrome. 
Nevertheless, vasculitis was not present at the initial diagnosis of RCC, and the disease 
was in remission at the onset of vasculitis. The fact that vasculitis improved with sunitinib 
discontinuation and prednisone and not with antitumor therapy is also against the 
possibility of a paraneoplastic manifestation. Clinical and laboratory examinations 
revealed no association of vasculitis with an infection or an underlying connective tissue 
disease. The mechanism by which sunitinib induces vasculitis is not clear. Sunitinib is 
supposed to reverse immunosuppression, enhancing the antitumor role of the immune 
system. Review of the literature reveals a correlation of sunitinib treatment with 
autoimmune diseases, and several preclinical and clinical studies suggest an 
immunotropic effect of the TKI molecules. The main mechanism is thought to be the 
inhibition of the VEGFR pathway which is expressed in dendritic cells, in T-regulatory 
cells, myeloid-derived suppressor cells and other cells of the immune system [15]. The 
high rate of hypothyroidism, a common adverse event in sunitinib-treated patients, is also 
supportive of its immunotropic role. Treatment of leukocytoclastic vasculitis is based on Case Rep Oncol 2011;4:385–391 
DOI: 10.1159/000331419 
Published online: 
August 18, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–6575 
www.karger.com/cro   
 
 
 
388
the control of the underlying disease or the discontinuation of the triggering factor. 
Nonsteroidal anti-inflammatory drugs can be used in mild cases, while corticosteroids 
and immunosuppressive agents, such as cyclophosphamide, are reserved for systemic 
disease. Regression of skin lesions by removing the suspected agent offers an indirect 
proof of causality. In our case, we administered prednisone in addition to the 
discontinuation of sunitinib due to the potential systemic involvement by vasculitis. 
Indeed, the patient presented with deep ulcers, which are uncommon in leukocytoclastic 
vasculitis and suggest arterial involvement and possible presence of systemic disease. The 
persistent remission of the skin lesions in spite of the reintroduction of sunitinib is in 
concert with the observation that many side effects of the new targeting molecules can be 
effectively treated without permanent discontinuation of anticancer therapy. 
Furthermore, dose modification of sunitinib and concomitant treatment with low doses 
of prednisone were the necessary manipulations that maintain the good result.  
However, the experience of such a long period of treatment with sunitinib as in our 
case is limited due to the relatively short overall survival of patients with mRCC. 
Consequently, such long-term adverse events of targeted therapies are largely unknown. 
The fact that this type of vasculitis is rarely associated with renal involvement is of great 
importance as most of these patients have a single kidney and frequently a degree of 
preexisting renal dysfunction. In our case, management of vasculitis consisted of small 
doses of prednisone. Sunitinib can be combined with prednisone but when long periods 
of therapy are required, an escalation of the sunitinib dose even to 62.5 mg can be 
considered due to the induction of the CYP3A4 enzyme by prednisone, which results in a 
faster catabolism of the drug. In our case, we did not attempt such dose escalation to 
avoid triggering of vasculitis.  
Conclusion 
In conclusion, sunitinib is responsible for various skin-related adverse events such as 
hand-foot syndrome and rash. Discrimination of these side effects from vasculitis is not 
always straightforward when based purely on clinical criteria, and the involvement of a 
dermatologist may be necessary. Knowing that a skin lesion can be the clinical 
manifestation of a systemic disorder such as a vasculitis, oncology providers should be 
aware of this rare but potentially serious, possible adverse effect of sunitinib.  
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Table 1. Laboratory examinations 
 Value  Normal  range 
White blood cells  2.4 × 10
3/μl 4,000–10,000 
Neutrophils  1.3 × 10
3/μl  00.40–74% 
Lymphocytes  0.7 × 10
3/μl  00.19–48% 
Hemoglobin 13.7  g/dl  00.14–17.5 
Platelet  147 × 10
3/μl  0.140–400 
Glucose 106  mg/dl  00.75–115 
Urea 42  mg/dl  00.18–50 
Creatinine 1.15  mg/dl  000.5–1.3 
ALT 30  U/l  000.5–40 
AST 40  U/l  000.5–40 
Calcium 9.3  mg/dl  008.8–10.2 
Phosphorus 3.5  mg/dl  002.7–4.5 
LDH 186  U/l 0.135–225 
ALP 58  U/l  00.35–104 
γ-GT 11  U/l  000.5–36 
Potassium 4  mmol/l  003.5–5.1 
Sodium 137  mmol/l  0.136–148 
ANA negative 
Anti-dsDNA negative 
AMA negative 
ASMA negative 
p-ANCA negative 
c-ANCA negative 
C3 107  mg/dl  0.075–180 
C4 24.8  mg/dl  0.. 10–40 
Rheumatoid factor  <9.8 U/ml  000.0–15 
Urinalysis protein  negative 
 hemoglobin  negative 
 blood  cells  0–1 
ALT = Alanine transferase; AST = aspartate transferase; LDH = 
lactate dehydrogenase; ALP = alkaline phosphatase; γ-GT = γ-
glutamate transferase; ANA = antinuclear antibodies; Anti-dsDNA = 
anti-double-stranded DNA antibodies; AMA = antimitochondrial 
antibodies; ASMA = anti-smooth muscle cell antibodies; p-ANCA = 
perinuclear antineutrophil cytoplasmic antibodies; c-ANCA = 
cytoplasmic antineutrophil cytoplasmic antibodies. 
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Fig. 1. Scattered purpuric nodules and plaques on the right tibia. The central hemorrhagic plaque has a 
necrotic center.  
 
 
 
Fig. 2. The epidermis exhibits acanthosis, hyperkeratosis and focal hyperkeratosis. The small vessels of 
the upper dermis show occasional transmural fibrinoid necrosis in association with minimal nuclear 
debris and some foci of neutrophils into the vessel wall as well as into the vascular lumen (HE, power 
×200). 
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